Incorporation of labeled methionine as a tissue tracer in broiler chickens

The objective of this study was to evaluate the process of L-methionine incorporation in the blood plasma, liver, breast muscle, and abdominal fat of 35- to 59-d-old broiler chickens using the carbon stable isotope (12C and 13C) technique for the estimation of methionine requirements. In this experiment, 51 male broiler chickens orally received a solution of L-[13C1] methionine (92 atm % 13C) at 29 µmol/kg live weight/h for 6 h. Three birds were sacrificed for tissue collection at times 0 h (control), 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 96, 120, 144, 168, and 336 h after the administration of the first dose. Tissue L-[13C1] methionine incorporation mass and percentage results were analyzed using Minitab 16 statistical software. Except for abdominal fat, tissue methionine levels gradually increased after the administration of the methionine solution. The calculated half-lives of methionine in the blood plasma, liver, and breast muscle were 2.52, 1.36, and 3.57 h, respectively, suggesting a greater rate of methionine incorporation in the liver, followed by blood plasma and breast muscle. The isotopic dilution showed that 2.81, 4.79, and 23.64% of the administered L-methionine were retained in the blood plasma, liver, and breast muscle, respectively. The methionine requirements of finisher broilers may be estimated using the carbon isotope technique, and approximately 3, 5, and 24% methionine is used for the synthesis of blood plasma, liver, and breast muscle, respectively, at the evaluated dose.

Incorporation of labeled methionine as a tissue tracer in broiler chickens

The objective of this study was to evaluate the process of L-methionine incorporation in the blood plasma, liver, breast muscle, and abdominal fat of 35- to 59-d-old broiler chickens using the carbon stable isotope (12C and 13C) technique for the estimation of methionine requirements. In this experiment, 51 male broiler chickens orally received a solution of L-[13C1] methionine (92 atm % 13C) at 29 µmol/kg live weight/h for 6 h. Three birds were sacrificed for tissue collection at times 0 h (control), 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 48, 72, 96, 120, 144, 168, and 336 h after the administration of the first dose. Tissue L-[13C1] methionine incorporation mass and percentage results were analyzed using Minitab 16 statistical software. Except for abdominal fat, tissue methionine levels gradually increased after the administration of the methionine solution. The calculated half-lives of methionine in the blood plasma, liver, and breast muscle were 2.52, 1.36, and 3.57 h, respectively, suggesting a greater rate of methionine incorporation in the liver, followed by blood plasma and breast muscle. The isotopic dilution showed that 2.81, 4.79, and 23.64% of the administered L-methionine were retained in the blood plasma, liver, and breast muscle, respectively. The methionine requirements of finisher broilers may be estimated using the carbon isotope technique, and approximately 3, 5, and 24% methionine is used for the synthesis of blood plasma, liver, and breast muscle, respectively, at the evaluated dose.(AU)

Modulation of methylmercury uptake by methionine: prevention of mitochondrial dysfunction in rat liver slices by a mimicry mechanism.

Methylmercury (MeHg) is an ubiquitous environmental pollutant which is transported into the mammalian cells when present as the methylmercury-cysteine conjugate (MeHg-Cys). With special emphasis on hepatic cells, due to their particular propensity to accumulate an appreciable amount of Hg after exposure to MeHg, this study was performed to evaluate the effects of methionine (Met) on Hg uptake, reactive species (RS) formation, oxygen consumption and mitochondrial function/cellular viability in both liver slices and mitochondria isolated from these slices, after exposure to MeHg or the MeHg-Cys complex. The liver slices were pre-treated with Met (250 µM) 15 min before being exposed to MeHg (25 µM) or MeHg-Cys (25 µM each) for 30 min at 37 °C. The treatment with MeHg caused a significant increase in the Hg concentration in both liver slices and mitochondria isolated from liver slices. Moreover, the Hg uptake was higher in the group exposed to the MeHg-Cys complex. In the DCF (dichlorofluorescein) assay, the exposure to MeHg and MeHg-Cys produced a significant increase in DFC reactive species (DFC-RS) formation only in the mitochondria isolated from liver slices. As observed with Hg uptake, DFC-RS levels were significantly higher in the mitochondria treated with the MeHg-Cys complex compared to MeHg alone. MeHg exposure also caused a marked decrease in the oxygen consumption of liver slices when compared to the control group, and this effect was more pronounced in the liver slices treated with the MeHg-Cys complex. Similarly, the loss of mitochondrial activity/cell viability was greater in liver slices exposed to the MeHg-Cys complex when compared to slices treated only with MeHg. In all studied parameters, Met pre-treatment was effective in preventing the MeHg- and/or MeHg-Cys-induced toxicity in both liver slices and mitochondria. Part of the protection afforded by Met against MeHg may be related to a direct interaction with MeHg or to the competition of Met with the complex formed between MeHg and endogenous cysteine. In summary, our results show that Met pre-treatment produces pronounced protection against the toxic effects induced by MeHg and/or the MeHg-Cys complex on mitochondrial function and cell viability. Consequently, this amino acid offers considerable promise as a potential agent for treating acute MeHg exposure.

Effect of protein malnutrition on redox state of the hippocampus of rat.

The protein malnutrition is a worldwide problem, affecting mainly newborns and children of developing countries. This deficiency reaches the brain in the most critical period of the development. Various consequences are related to this insult, such as memory disturbance, learning, and behavioral impairment. Protein content of the diet plays an important role on antioxidant mechanisms. This study observed the effects of protein malnutrition on rat hippocampus redox state. Wistar rats were separate in four groups, receiving different diets: first group with 25% casein, protein deficient group with 8% casein, and the same two groups supplemented with methionine (0.15%). Diets were isocaloric and were administered since the prenatal period up to the sacrifice. Rats were decapitated at 21 or 75 days old and hippocampus were isolated for measuring the lipoperoxidation by TBARS method, protein oxidative damage by carbonyl (DNPH) levels, and the activities of antioxidant enzymes superoxide dismutase (SOD) and catalase (CAT). There was significant alterations in the activities of the enzyme SOD, lipoperoxidation, and protein oxidation in hippocampus of 21 and 75 day-old rats fed with 25% of protein with methionine and the groups fed with low levels of protein (8%) both supplemented or not with methionine. Our data suggest that both the content of protein in the diet and the essential amino acid methionine may alter the antioxidant system and the redox state of the brain.

Involvement of methionine residues in the fast inactivation mechanism of the sodium current from toad skeletal muscle fibers.

The role of methionine residues on the fast inactivation of the sodium channel from toad skeletal muscle fibers was studied with the mild oxidant chloramine-T (CT). Isolated segments of fibers were voltage clamped in a triple Vaseline gap chamber. Sodium current was isolated by replacing potassium ions by tetramethylammonium ions in the external and internal solutions. Externally applied chloramine-CT was found to render noninactivating a large fraction of sodium channels and to slow down the fast inactivation mechanism of the remainder fraction of inactivatable channels. The action of CT appeared to proceed first by slowing and then removing the fast inactivation mechanism. The voltage dependence of the steady-state inactivation of the inactivatable CT-treated currents was shifted +10 mV. CT also had a blocking effect on the sodium current, but was without effect on the activation mechanism. The effects of CT were time and concentration dependent and irreversible. The use of high CT concentrations and/or long exposure times was found to be deleterious to the fiber. This side effect precluded the complete removal of fast inactivation. The effects of CT on the fast inactivation of the sodium current can be explained assuming that at least two methionine residues are critically involved in the mechanism underlying this process.

Hiperhomocist(e)inemia / Hyperhomocyst(e)inemia

A través de numerosos datos derivados de observaciones epidemiológicas y experimentales, se ha establecido que existe una correlación positiva entre la hiperhomocist(e)inemia (HH(e)) y las enfermedades vasculares. Los datos clínicos confirman que la homocisteína (Hcy) es un factor de riesgo independiente de afecciones arteriales oclusivas (coronaria, cerebrovascular y periféricovascular) así como también trombosis venosa periférica. Este aminoácido contiene un sulfhidrilo y se forma por la desmetilación de la metionina. Es normalmente catalizado a cistationina por la enzima cistationina ß-sintetasa (CBS), dependiente de fosfato de piridoxal. Homocisteína también es remetilada a metionina por las enzimas 5-metiltetrahidrofolato-Hcy metiltransferasa (metionina sintetasa), dependiente de vitamina B12 y betaína-Hcy metiltransferasa. Estados nutricionales tales como deficiencias en vitamina B12, vitamina B6 o folato y defectos genéticos de las enzimas CBS o 5,10-metilentetrahidrofolato reductasa, pueden contribuir al aumento de los niveles plasmáticos de Hcy. La patogénesis del daño vascular inducido por Hcy puede ser multifactorial: daño directo sobre el endotelio, aumento de la peroxidación de lipoproteínas de baja densidad, incremento de tromboxano A2 plaquetario o menor activación de la proteína C. En el presente trabajo, se describen los más recientes estudios acerca de la patogénesis de la HH(e) y las implicancias para una óptima terapia (AU)

Hiperhomocist(e)inemia / Hyperhomocyst(e)inemia

A través de numerosos datos derivados de observaciones epidemiológicas y experimentales, se ha establecido que existe una correlación positiva entre la hiperhomocist(e)inemia (HH(e)) y las enfermedades vasculares. Los datos clínicos confirman que la homocisteína (Hcy) es un factor de riesgo independiente de afecciones arteriales oclusivas (coronaria, cerebrovascular y periféricovascular) así como también trombosis venosa periférica. Este aminoácido contiene un sulfhidrilo y se forma por la desmetilación de la metionina. Es normalmente catalizado a cistationina por la enzima cistationina ß-sintetasa (CBS), dependiente de fosfato de piridoxal. Homocisteína también es remetilada a metionina por las enzimas 5-metiltetrahidrofolato-Hcy metiltransferasa (metionina sintetasa), dependiente de vitamina B12 y betaína-Hcy metiltransferasa. Estados nutricionales tales como deficiencias en vitamina B12, vitamina B6 o folato y defectos genéticos de las enzimas CBS o 5,10-metilentetrahidrofolato reductasa, pueden contribuir al aumento de los niveles plasmáticos de Hcy. La patogénesis del daño vascular inducido por Hcy puede ser multifactorial: daño directo sobre el endotelio, aumento de la peroxidación de lipoproteínas de baja densidad, incremento de tromboxano A2 plaquetario o menor activación de la proteína C. En el presente trabajo, se describen los más recientes estudios acerca de la patogénesis de la HH(e) y las implicancias para una óptima terapia